Skip to content

Cash ratio at other companies

Biogen logo
BiogenBIIB
1.1×+0.6×
PTC Therapeutics logo
PTC TherapeuticsPTCT
0.9×-1.6×
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
0.6×+0.3×
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
4.2×+1.6×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
1.1×-2.5×
Arrowhead Research logo
Arrowhead ResearchARWR
0.6×-0.2×

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$5.67B+85.5%
Enterprise value$5.45B+82.6%
P/S170.9×

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Calculated from Scholar Rock’s reported figures.

Based on the most recent quarter.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's cash ratio?
Scholar Rock (SRRK) reported cash ratio of 7.2× in Q1 2026.
How has Scholar Rock's cash ratio changed year-over-year?
Scholar Rock's cash ratio increased by 96.7% year-over-year, from 3.7× to 7.2×.
What is the long-term trend for Scholar Rock's cash ratio?
Over 5 years (2020 to 2025), Scholar Rock's cash ratio has grown at a 9.2% compound annual growth rate (CAGR), from 3.8× to 5.8×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.